Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.

Psychiatry research - 1 Sept 2019

Walden Lucas M, Brandl Eva J, Tiwari Arun K, Cheema Sheraz, Freeman Natalie, Braganza Nicole, Kennedy James L, Müller Daniel J

Abstract excerpt

Individuals carrying genetic variants that result in non-extensive CYP2D6 and CYP2C19 enzyme activity seem to be more prone to non-response and side-effects of psychotropic medications. Therefore, tailoring prescriptions using genetic information may improve patient outcomes. This study examined treatment outcome in psychiatric care after CYP2D6 and CYP2C19 genetic information was provided to patients and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP2D6

Share to Depressive Disorder

Share to Drug-Related Side Effects and Adverse Reactions

Share to Pharmacogenetics

Share to Psychotic Disorders

Source

Identifiers

PMID: 29699889
DOI: 10.1016/j.psychres.2018.02.055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.PMID 29699889Read ↗

Towards the implementation ofCYP2D6andCYP2C19genotypes in clinical practice: Update and report from a pharmacogenetic service clinicSemantic proximity Read ↗

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responsesSemantic proximity Read ↗

Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapySemantic proximity Read ↗

Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?Semantic proximity Read ↗

A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 e CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder.Semantic proximity Read ↗

Clinical Utility and Economic Impact of CYP2D6 Genotyping.Semantic proximity Read ↗

Psychiatric pharmacogenomic testing in clinical practiceSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity Read ↗

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and FutureSemantic proximity Read ↗

Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.Semantic proximity Read ↗

Frequencies of CYP2C19 and CYP2D6 gene variants in a German inpatient sample with mood and anxiety disorders.Semantic proximity Read ↗

Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.